Expertise in
1
conditions

Dr. Mark Lee

Dermatology
MEDcare Associates P.A.
4499 Medical Dr Ste 102, 
San Antonio, TX 
Referral may be required
Expertise in
1
conditions
MEDcare Associates P.A.
4499 Medical Dr Ste 102, 
San Antonio, TX 

Overview

Mark Lee is a Dermatologist practicing medicine in San Antonio, Texas.

Dr. Lee is highly rated in 1 condition, according to our data. His clinical expertise encompasses Atopic Dermatitis, Actinic Keratosis, Psoriasis, and Melanoma.

He is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 22 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

MEDcare Associates P.A.
4499 Medical Dr Ste 102, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Randomized, Double-Blind, Vehicle-Controlled Ascending Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASN008 Topical Gel in Healthy Volunteers and Subjects With Atopic Dermatitis
A Phase 1, Randomized, Double-Blind, Vehicle-Controlled Ascending Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASN008 Topical Gel in Healthy Volunteers and Subjects With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

18 Total Publications

Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.
Journal: JAMA dermatology
Published: June 25, 2025
Similar Doctors
Expertise in
45
conditions
Dr. Mary Altmeyer
Dermatology
Expertise in
45
conditions
Dr. Mary Altmeyer
Dermatology
Referral may be required

Mission Dermatopathology Laboratory LLC

2620 McCullough Ave, 
San Antonio, TX 
 (6.3 miles away)
210-664-4675
Languages Spoken:
English
See accepted insurances

Mary Altmeyer is a Dermatologist practicing medicine in San Antonio, Texas. Dr. Altmeyer is highly rated in 45 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Bowen's Disease, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Expertise in
26
conditions
Dr. Eloise Atkinson
Dermatology
Expertise in
26
conditions
Dr. Eloise Atkinson
Dermatology
Referral may be required

Office

18540 Sigma Rd, 
San Antonio, TX 
 (8.9 miles away)
210-490-4661
Languages Spoken:
English
See accepted insurances

Eloise Atkinson is a Dermatologist practicing medicine in San Antonio, Texas. Dr. Atkinson is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Universal Acquired Melanosis, Liver Spots, and Warts.

Expertise in
36
conditions
Dr. Chantal Devillena
Dermatology
Expertise in
36
conditions
Dr. Chantal Devillena
Dermatology
Referral may be required

Office

18540 Sigma Rd, 
San Antonio, TX 
 (8.9 miles away)
210-490-4661
Languages Spoken:
English
See accepted insurances

Chantal Devillena is a Dermatologist practicing medicine in San Antonio, Texas. Dr. Devillena is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Melanocytic Nevus, Giant Congenital Nevus, and Actinic Keratosis.

Frequently Asked Questions about Dr. Mark Lee

How do I make an appointment with Dr. Mark Lee?

You can book an appointment with Dr. Mark Lee by calling their office at 210-614-0402. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark Lee a top-rated expert for Atopic Dermatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark Lee is classified as an Advanced expert for Atopic Dermatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark Lee specialize in?

While Dr. Mark Lee is a Dermatology, they have specific expertise in Atopic Dermatitis, Actinic Keratosis, and Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Mark Lee participate in research or clinical trials?

Yes. Dr. Mark Lee has published 18 articles and abstracts on conditions like Atopic Dermatitis. You can view a list of Dr. Mark Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark Lee accept my insurance?

Dr. Mark Lee accepts most major insurance plans, including Health Care Services Corporation and UnitedHealthcare. We recommend calling the office directly at 210-614-0402 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile